Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. DexCom develops continuous glucose monitoring (CGM) devices that help ...

That included stats showing Dexcom’s worldwide user base growing by about 25%, to more than 2.8 million customers. At the same time, Dexcom predicted its year-long sales would continue to grow ...

Dexcom also plans to add integrations with meal-tracking apps such as MyFitnessPal in response to user feedback. The company has begun work on a next-generation CGM. Sayer said the sensor will be ...

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from Leerink Partners maintained a Buy rating on the ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an ...

North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate ...